NCT03774082 - Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

February 25, 2022

Study Completion Date

August 26, 2024

Conditions

Graft vs Host Disease

Interventions

DRUG

INC424

"Ruxolitinib was taken orally based on age groups as follows:~Group 1 (\>=12y to \<18y): 10mg bid as tablet Group 2 (\>=6y to \<12y): 5mg bid as tablet or liquid Group 3 (\>=2y to \<6y): 4mg/m2 bid as liquid"

Trial Locations (21)

1330

Novartis Investigative Site, Adana

10002

Novartis Investigative Site, Taipei

10400

Novartis Investigative Site, Bangkok

197022

Novartis Investigative Site, Saint Petersburg

411004

Novartis Investigative Site, Pune

560099

Novartis Investigative Site, Bangalore

600035

Novartis Investigative Site, Tamil Nadu

04039 001

Novartis Investigative Site, São Paulo

M5G 1X8

Novartis Investigative Site, Toronto

150 06

Novartis Investigative Site, Prague

110 085

Novartis Investigative Site, Delhi

00165

Novartis Investigative Site, Roma

466 8560

Novartis Investigative Site, Nagoya

330 8777

Novartis Investigative Site, Saitama

833 40

Novartis Investigative Site, Bratislava

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

CH - 8032

Novartis Investigative Site, Zurich

07000

Novartis Investigative Site, Antalya

07070

Novartis Investigative Site, Antalya